Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University First Hospital
About this trial
Patients with mechanical ventilation in the intensive care unit (ICU) often develop anxiety and agitation, sleep distuebances, and delirium. Delirium occurrence is associated with worse early and long-term outcomes. Dexmedetomidine and ketamine are recommended for sedation and analgesia in ICU patients, but each may induce side effects. The sedative effects of dexmedetomidine can help mitigate the psychiatric side effects of esketamine. Recent studies showed that dexmedetomidine-esketamine combination improved analgesia and sleep quality without increasing psychiatric side effects. This trial is designed to test the hypothesis that dexmedetomidine-esketamine combination for sedation and analgesia in ICU patients with mechanical ventilation may reduce delirium and improve respiratory recovery.
Eligibility criteria
Qualifiers
Aged ≥18 years;
Receiving invasive or non-invasive mechanical ventilation in the ICU, with an expected duration ≥24 hours;
Require sedation as judged by ICU physicians.
Disqualifiers
Pregnant or lactating women;
History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;
Unable to communicate due to coma, severe dementia, or language barrier prior to invasive/non-invasive mechanical ventilation;
After stroke, hypoxic encephalopathy, traumatic brain injury, or neurosurgery;
Trial design
Treatments tested in this trial
- Dexmedetomidine-Esketamine Combination
- Dexmedetomidine
Treatment groups
1,508 Participants
are divided into 2 treatment groupsSponsors and collaborators
Peking University First Hospital
Lead sponsor
Peking University International Hospital
Collaborator
Tianjin Medical University General Hospital
Collaborator
Source ClinicalTrials.gov